In vitro antimicrobial activity of marbof loxacin and enrof loxacin against bacterial strains isolated from companion animals

Schweizer Archiv fur Tierheilkunde

Volumn 149, Issue 6, 2007, Pages 265-271

  Farca, A M ^a,b   Cavana, P ^a   Robino, P ^a   Nebbia, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE   (Italy)

Author keywords

Antimicrobial sensitivity in vitro; Cat; Dog; Enrofloxacin; Marbofloxacin

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS;

ANTIINFECTIVE AGENT; ENROFLOXACIN; MARBOFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; CAT; CAT DISEASE; DOG; DOG DISEASE; DOSE RESPONSE; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; MICROBIOLOGICAL EXAMINATION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CAT DISEASES; CATS; COLONY COUNT, MICROBIAL; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; QUINOLONES; TREATMENT OUTCOME;

EID: 34250737353     PISSN: 00367281     EISSN: None     Source Type: Journal    
DOI: 10.1024/0036-7281.149.6.265     Document Type: Article

References (42)

1. Brown S.A.'Fluoroquinolones in animal health.J.Vet. Pharmacol. Ther. 1996, 19: 1-14.
2. BurkhardtJ. E., Waltcrspdl J. N., Schaad U. B.: Quinolone arthropathy in animals versus children. Clin. Infect. Dis. 1997, 25:1196-1204.
3. Capriali A., Busani L., Martel J, I., Elmtith R,: Monitoring of antibiotic resistance in bacteria of animal origin: epidemio-logical and microbiological methodologies. Int. J. Antimicrob. Agents 2000, 14 :295-301.
4. Center C. C., SchneiderM.,Tontain PL.: Comparative kinetics of two orally administered fluoroquinolones in dog: enrofloxacin versus marbofloxacin. Revue Med. Vet. 1996, 147:703-716.
5. Cester C. C., Toutain P L.: A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in the dog.J. Pharm. Sei. 1997, 86:1148-1155.
6. Cheng T.K.,ChuYW, Chu MY, Ma C.H.,Yung R.W,Kam K. M.;Plasmid- mediated resistance to ciprofloxacin and cefotaxime in clinical isolates of Salmonella enterica seritype Enteriditis in Hong Kong.J. Antimicrob. Chemother. 2005, 56:586-589.
7. Cohn L.A., Gary A. T., Fates W H., Madsen R. W: Trend in Fluoroquinolone resistance of bacteria isolated from canine urinary tracts.J.Vet. Diagn. Invest. 2003, 15: 338-343.
8. Damborg P., Olsen K. E., Moller Nielsen E., Guardabassi L.: Occurrence of Campylobacter jejuni in pets living with human patients infected with C. jejuni. J. Clin. Microbiol. 2004, 42:1363-1364.
9. EME A, European Medicines Agency, Committee for medicinal products for veterinary use, 18 January 2006, London.
10. Frazicr D. L., Thompson L., Trettien A., Evans E. I, : Comparison of fluoroquinolone pharmacokinetic parameters after treatment with rnarbofloxacin, enrofloxacin, and difloxacin in dogs.J.Vet. Pharmacol.Therap. 2000, 23:293-302.
11. Gclatt K. N., Van der WoerdtA., Ketring K. L, Andrew S. E., Brooks D. E., Biros D.J., Denis H. M., CutlerT.J.: Enrofloxacin-associated retinal degeneration in cats. Vet. Ophthal. 2001, 4:99-106.
12. Goodman L. S., Oilman's A,: Antimicrobial agents. In: The pharmacological basis of therapeutics. Eds.McGraw-Hill, Medical Publishing Division, New York, 2001, 1171-1187.
13. Guardabassi L., Locher M, E, JacobsonA, 'Trasmission of multiple antimicrobial resistant Staphylococcus intermedius between dogs affected by deep pyoderma and their owners. Vet. Microbiol. 2004, 98:23-27.
14. Hayem G., Petit P. X., Le Vacher M., Gandin C., Kahr M. E, PoddaloJ.J.: Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 1994, 38:243-247.
15. HeitK'H E,: Comparative serum pharmacokinetics of the fluoroquinilones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration.J. Vet. Pharmacol.Therap. 2002, 25:1-5.
16. Heuer E.,Jemen VE, Hammerum A. M. : Antimicrobial drug consumption in companion animals. Emerg. Infec. Dis. 2005, 11:344-345.
17. Horspool L.J., Van Laar P., Van Den Bos R., Mau'hinney I: Treatment of canine pyoderma with ibafloxacin and marbofloxacin-fluoroquinolones with different pharmacokinetic profiles. J. Vet. Pharmacol.Therap. 2004, 27:147-153.
18. Kilmartin D., Morris D., O'Hare C., Corbett-Fecney G., Cormican M,: Clonal expansion may account for high levels of quinolone resistance in Salmonella enterica serovar Enteriditis. Appl. Environ. Microbiol. 2005, 71:2587-2591.
19. Lipsky B.A., Baker C.A.: Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 1999, 28:352-364.
20. Marbofloxacin reference book, 1999,Vetoquinol, France.
21. McGowan J. E. : Does antibiotic restriction prevent resistance? New Horizons 1996, 4:370-376.
22. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial disk and dilution susceptibility test for bacteria isolated from animals. Approved Standard M31-A. National Committee for Clinical Laboratory Standards,Wayne, Pa Petzinger E.: GyrasehemmstofFc, cine neue Klasse von Chemotherapeutika. Tierarztl. Prax. 1991,19:14-20.
23. Norrby S. R.: Side effects of quinolones: comparisons between quinolones and other antibiotics. Eur.J. Clin. Microbiol. 1991, 10:378-383.
24. Piddock L. J. V: Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995, 49 (Suppl.2): 29-35.
25. Prescott J. F., Hanna W.J. B., Reid-Smith R.,DrostK.,- Antimicrobial drug use and resistance in dogs. Can.Vet. J. 2002, 43: 107-116.
26. Reinhardt A. K., Bébéar C. M., Kobisch M., Kcnipf I, GauticrBouchardon A. V.: Characterization of mutations in DNA gyrasc and topoisomerase IV involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro. Antimicrob. Agents Chemother. 2002, 46:590-593.
27. Rodrigites J., Thomazini C, M., Lopes C.A., Dantas L, O.: Cuncurrent infection in dog and colonization in a child witfi a human enteropathogenic Escherichia coli clone. J. Clin. Microbiol. 2004, 42:1388-1389.
28. Rosenstiel N. V.,Adam D.: Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs 1994, 47:872-901.
29. Schneider M., Thomas V, Boisgame B., Deleforge J.: Pharmaco-kinetics of niarbofloxacin in dogs after oral and parenteral administration.J.Vet. Pharmacol.Therap. 1996, 19:56-61.
30. Schwarz S., Roberts M. C.,Wcrckenthin C, Pang J., Lange C.: Tctracydinc resistance in Staphylococcus spp. from domestic animals.Vet. Microbiol. 1998, 63: 217-227.
31. Spreng M., Deleforge J., Thomas V, Boisgame B., Drugeon H.: Antibacterial activity of niarbofloxacin. A new fluoroquino-lone for veterinary use agaist canine and feline isolates.J.Vet. Pharmacol.Therap. 1995, 18:284-289.
32. StantonA. Glanz: Statistica per discipline biomediche. 2 ed. Me Graw-Hill. Libri Italia srl ed. 1988, 180-210.
33. Van Cutsm P.M., Babish J. G., Schwark W.S.:'The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. CornellVct. 1990, 80:173-186.
34. Van den Bogaard A. E., Stobberingh E. E.: Antibiotic usage in animals. Impact on bacterial resistance and public health. Drugs 1999, 58:589-607.
35. Van Immersed P., Pasmans F., De Buck J., Rychlik L, Hradecka H., Collard J., Wildemauwe C, Heyndrickx M., Ducatelle R., Haesebrouck E: Cats as a risk for transmission of antimicrobial drug-resistant Salmonella. Emerg. Infec. Dis. 2004, 10: 2169-2174.
36. Walker R. D., Stein G. E., HauptmanJ. G., McDonald K. H. : Pharmacokinctic evaluation of enrofloxacin administered orally to healthy dogs. Am. J.Vet. Res.1992, 53: 2315-2319.
37. Walker R. D.,Thornsberry C. : Decrease in antibiotic susceptibility or increase in resistance? J. Antimicrob. Chemother. 1998, 41:1-4.
38. Walker A. L. Jang S. S., Hirsh D. C. : Bacteria associated with pyothorax of dogs and cats: 98 cases (1989-1998),J. Am.Vet. Med.Assoc. 2000, 216:359-363.
39. Wang M., Tran J. H., Jacoby G.A., ZhangY,Wang F, Hooper D. C. : Plasmid mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob. Agents Chemother. 2003, 47:2242-2248.
40. Weber von A., Wachowitz R., Fuchs D., Weigl U., Pfqfftnger I.: Resistenzverhalten von zwei fluochinolonen. Tierarztl. Umschau 2000, 55: 397-400.
41. Wiebe V, Hamilton P.: Fluoroquinolone-induccd retinal degeneration in cats.J. Am.Vet. Med.Assoc. 2002, 221:1568-1571.
42. Wolfson J. S., Hooper D. C. : Overview of fluoroquinolone safety.Am.J. Med. 1991, 91(Suppl.6A): 153-161.